Fact CheckerSign in

NCT00099086CompletedPhase 1

Docetaxel, Radiation Therapy, and Hormone Therapy in Treating Patients With Locally Advanced Prostate Cancer

Phase I Trial of Concurrent Taxotere With Radiation Therapy and Hormonal Therapy For Clinically Localized High Risk Prostate Cancer

Source: ClinicalTrials.gov · Last updated 31 Jan 2024

Brief summary (registry, in English)

This phase I trial is studying the side effects and best dose of docetaxel when given with radiation therapy and hormone therapy in patients with locally advanced prostate cancer.

Status (registry)
Completed
Phase (registry)
Phase 1
Study type
Interventional
Enrollment
20 (actual)
First submitted
8 Dec 2004
Start date
16 Jan 2007
Primary completion date
20 Jan 2011
Lead sponsor
Medical University of South Carolina
NCT number
NCT00099086

What you commit to

  • Study type: Interventional · Phase 1
  • Participants enrolled: 20
  • From 16 Jan 2007 to the primary completion date, 20 Jan 2011
  • No sites listed in no country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • 1\. No history of severe hypersensitivity reaction to docetaxel or other drugs formulated with Polysorbate 80

Who the study is looking for

  • Histologically confirmed adenocarcinoma of the prostate with one of the prognostic factors specified in the protocol. No pelvic lymph node disease that would necessitate pelvic radiotherapy. No radiologic evidence of metastatic disease on bone scan or on CT scan or MRI of the abdomen or pelvis
  • No prior radiation therapy, chemotherapy, immunotherapy or alternative therapy for prostate cancer. Greater than 4 weeks since any major surgery.
  • Performance status 0-2
  • Must meet criteria for acceptable lab values as outlined in the protocol.
  • Peripheral neuropathy must be greater than or equal to 1
  • Men of childbearing potential must be willing to consent to using effective contraception while on treatment and for at least 3 months thereafter.

Age in the registry: 18 years to - · Sex: Male · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

This page is information, not medical advice. Discuss any trial with your doctor.